Check for updates

OPEN ACCESS

EDITED BY Yuekang Xu, Anhui Normal University, China

REVIEWED BY

Hui Chen, Chinese Academy of Medical Sciences and Peking Union Medical College, China Takeshi Nitta, The University of Tokyo, Japan

*CORRESPONDENCE Chen Chen chenchen@ahmu.edu.cn Yanan Yang yang.yanan@ahmu.edu.cn

SPECIALTY SECTION

This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology

RECEIVED 09 June 2022 ACCEPTED 28 July 2022 PUBLISHED 16 August 2022

CITATION

Chen C, Chen A and Yang Y (2022) A diversified role for γδT cells in vector-borne diseases. *Front. Immunol.* 13:965503. doi: 10.3389/fimmu.2022.965503

COPYRIGHT

© 2022 Chen, Chen and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A diversified role for $\gamma \delta T$ cells in vector-borne diseases

Chen Chen^{1*}, Aibao Chen² and Yanan Yang^{3*}

¹Department of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China, ²Department of Cell Biology, School of Life Sciences, Anhui Medical University, Hefei, China, ³Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China

Vector-borne diseases have high morbidity and mortality and are major health threats worldwide. $\gamma\delta T$ cells represent a small but essential subpopulation of T cells. They reside in most human tissues and exert important functions in both natural and adaptive immune responses. Emerging evidence have shown that the activation and expansion of $\gamma\delta T$ cells invoked by pathogens play a diversified role in the regulation of host-pathogen interactions and disease progression. A better understanding of such a role for $\gamma\delta T$ cells may contribute significantly to developing novel preventative and therapeutic strategies. Herein, we summarize recent exciting findings in the field, with a focus on the role of $\gamma\delta T$ cells in the infection of vector-borne pathogens.


KEYWORDS

 $\gamma\delta T$ cells, vector-borne diseases (VBDs), host immune response, infection, pathogens

Introduction

Vector-borne emerging and re-emerging infectious diseases are major public health problems worldwide, accounting for more than one sixth of all infectious diseases (1, 2). They are caused by pathogens carried and transmitted by vectors, such as mosquitos, ticks, fleas, flies, lice, snails, and triatomine bugs (Figure 1).

WHO recently announced the spread of the vector-borne pathogens, primarily including parasites, viruses and bacteria (https://www.who.int/zh/news-room/fact-sheets/detail/vector-borne-diseases). Specifically, the parasites included were lymphatic filariasis (mosquito), schistosoma (aquatic snail), onchocodium filariasis (black fly) and trypanosoma (triatomine bug, tsetse fly) and etc; viruses include mosquito-borne chikungunya fever, dengue, lymphatic filariasis, Rift Valley fever, yellow fever, Zika, and tick-borne Crimean-Congo hemorrhagic fever virus, borrelia burgdorferi, tick-borne encephalitis virus, and etc.; and bacteria mainly include Typhoid, Coxella bainiensis, spot fever rickettsia, and etc. (Figure 1).



Vector-borne diseases may not be directly disseminated between humans. Under certain circumstances, they can be transmitted to different hosts through the bite by pathogeninfected vectors (3, 4). As emerging infectious diseases (including vector-borne diseases) have certain relationships with social and economic development (5), a better understanding of the emerging and recurrent infectious diseases, especially how these diseases are transmitted, has profound significance for both human health and social development.

In response to pathogen invasion, human immune system acts as an advanced structural and functional architecture, in which all components (e.g. immune organs and cells, inflammatory factors, humoral factors, cytokines and chemokines) are highly orchestrated towards eliminating the invaded pathogen (6). During the invasion, both innate and adaptive immune responses can be triggered. Compared to innate immunity, adaptive immunity utilizes antigen and antibody specificity to eliminate the pathogen, thereby maintaining a steady state of the host and creating immunological memory for combating potential re-invasion of the same pathogen.

Different leukocytes, for example B and T cells, are known to play differential roles during these processes (7). T cells can be categorized to conventional T cells ($\alpha\beta$ T cells) and unconventional T cells ($\gamma\delta$ T cells) according to the types of their cell surface antigen receptors (8). Although $\alpha\beta$ T and $\gamma\delta$ T originate (differentiate) from the same thymic precursors, there are huge differences of biological functions and structures between the two types of T cells. The $\alpha\beta$ T cell receptors are expressed by ~95% of the T cells in the spleen, lymph nodes, and circulation system, and by ~60-70% of T cells in the peripheral blood. They have α and β chains and exhibit MHC restriction during the recognition of antigens (9).

On the contrary, the $\gamma\delta T$ cells express γ and δ chains of T cell receptors, account for ~5-15% T cells in the peripheral blood, and do not have MHC restriction during the recognition of antigens (10, 11). At the initial stage during the invasion of pathogens, $\gamma\delta T$ cells apparently exert innate immunity functions (6), so that they can rapidly respond by recognizing some common antigen components expressed by the invading pathogens, including glycolipids, glycoproteins, and mycobacterial derivatives (12). Although $\gamma\delta T$ cells have been known to act primarily in innate immunity, more and more findings have shown that these cells also exert fundamental functions in adaptive immune responses, for instance, by secreting cytokines and presenting antigens. Therefore, they have been considered as a bridge connecting innate immunity and adaptive immunity. However, the biological functions of $\gamma\delta T$ cells are not entirely dependent on HLA recognition mechanism.

 $\gamma \delta T$ accounts for only a small part of the T cell population and is widely distributed in different parts of the human body, such as skin and intestinal tract (7). Human $\gamma \delta T$ cells are mainly categorized by the usage of δ chain, whereas mouse $\gamma \delta T$ cells are often categorized by the usage of γ chains. As such, human $\gamma \delta T$ cells can be divided into $\gamma \delta 1$, $\gamma \delta 2$, and $\gamma \delta 3$ T cells (13), with their distribution and function varying from each other (14). $\gamma \delta 1$ T cells are mainly distributed in the mucosal epithelium and play an important role in cell infection by listeria and cytomegalovirus. $\gamma \delta 2$ T cells are relatively high in peripheral blood $\gamma\delta T$ cells and show strong immune response to mycobacterium and influenza virus (15, 16). They destroy pathogens or infected cells by interacting rapidly with them (17, 18). $\gamma\delta 3$ T cells, which account for a small proportion of $\gamma\delta T$ cell and are abundant in the liver, act during chronic viral infection (19).

The common and more harmful vector-borne diseases include dengue virus, Japanese encephalitis, Lyme disease and malaria. $\gamma\delta T$ cells play a key role in the host immune responses to the invasion of arbo-borne pathogens. More and more studies have shown that $\gamma\delta T$ cells are critical for antiviral and immunomodulatory activities in the first stage of arbo-borne pathogen infection. They are activated and participate in innate immune responses by producing cytokines associated with appropriate T-assisted responses during the early stages of microbial infection, either intracellular or extracellular (20). In addition to directly fighting against invading pathogens, $\gamma\delta T$ cells can also respond by recruiting other natural immune cells such as neutrophils and macrophages (21).

Infectious diseases are caused mainly by pathogenic microorganisms such as bacteria, viruses and parasites. $\gamma\delta T$ cells play important roles in responding to the invasion of common pathogens. Zhao and colleagues have summarized the role played by $\gamma\delta T$ cells in host responses to

mycobacterium tuberculosis, Listeria monocytogenes, influenza viruses, HIV, EBV, and HBV (13). However, little is known about the effects of vectors on host $\gamma\delta T$ cells. Emerging vectorborne infectious diseases are an important part of emerging infectious diseases and have been in an intensified form globally. Many social and natural factors, including environmental pollution and modern transportation and logistics, make it more convenient for vectors to transmit arboreal pathogens.

Traditionally, many vector-borne diseases can be treated by antibiotics-based therapeutics. However, at least partly due to the antibiotics abuse in clinic, a variety of pathogens have developed resistance to common antibiotics, leading to poor clinical outcomes when using antibiotics to treat infected patients (22). To address this problem, it is critical for developing novel therapeutic approaches. In the past decades, scientists and clinicians have focused on the roles of conventional T cells-mediated immune responses during the pathogen infection. Notably, more and more evidence has uncovered previously-unrecognized key roles of unconventional T cells in this process. Therefore, we feel it is important to summarize recent progresses in the field investigating the functions of T cells (Table 1), especially the unconventional $\gamma\delta T$ cells, during the host immune responses to vector-borne pathogens, such as plasmodium, borrelia

TABLE 1 Potential roles for $\gamma\delta T$ cells in vector-borne diseases.

| Disease | Pathogen | Involved $\gamma \delta T$ cells and their potential roles | References |
|---------------------------------------|----------------------------|--|----------------------|
| Chikungunya (mosquito-borne) | chikungunya fever virus | $\gamma\delta T$ cells; likely involved in promoting protective immunity | (23–25) |
| Rift Valley Fever (mosquito-borne) | Rift Valley Fever virus | CD11b ⁺ $\gamma \delta T$; may be critical for the host responses in sheep | (26–28) |
| Yellow fever (mosquito-borne) | Yellow fever virus | $\gamma\delta 2\mathrm{T}$ cells; can respond quickly to virus infection and produce IFN- γ | (29) |
| Dengue fever (mosquito-borne) | Dengue fever virus | γ δ2-T-cells; may serve as the early source of IFN- γ during dengue virus infection and promote the host immune responses by eliminating the virus-infected cells | (30–37) |
| Zika fever (mosquito-borne) | Zika virus | γδ2T; unclear | (38–40) |
| West Nile fever (mosquito-borne) | West Nile virus | $\gamma\delta T$ cells; may serve as the main source of IFN- γ and may also promote DC maturation and CD4 $^{+}$ T cell infiltration | (41-45) |
| Malaria (mosquito-borne) | plasmodium parasite | $\gamma\delta T$ cells, Vg9Vd2 subpopulation, and $\gamma\delta 2^+$ $\gamma\delta T$ cells; play both anti-pathogen and pathogenic roles | (46–60) |
| Lyme disease (tick-borne) | borrelia burgdorferi | $\gamma \delta T$ cells; may act indirectly through the actions of Toll-like receptors of DCs or monocytes, and may also act to activate the host acquired immunity during the infection of the pathogen | (61–66) |
| Tularaemia (tick-borne) | Francisella tularensis | $\gamma\delta T$ cells can be increased and maintained for up tyo a year in the peripheral blood from tularaemia patients | (67–69) |
| Leishmaniasis | leishmania | γδT cells; a potential role for γδT cells in eliminating the infected parasites, but long-term parasite infection may lead to γδT lymphoma | (70–73) |
| South American trypanosomiasis | Trypanosoma cruzi | $\gamma \delta T$ cells; may act by secreting IL-10 to facilitate host responses | (74) |

burgdorferi, and dengue fever, with a hope to accelerate our efforts in developing novel and effective clinical therapeutic strategies.

Immune responses of the host $\gamma \delta T$ cells to mosquito-borne pathogens

Mosquito-borne viruses

Chikungunya

Chikungunya is caused by the infection of chikungunya fever virus. Its clinical manifestations include headache, fever, and serious joint pains (23–25). Vectors for chikungunya fever mainly include Aedes Aegypti and Aedes albopictus (also called Asian tiger mosquito) (75). Currently, there is no effective drugs or vaccines available for treating or preventing chikungunya (76). Different T cell family members play differential roles after the invasion of chikungunya fever. Rapidly accumulated CD8⁺ T cells have been detected in the joints of mice that are acutely infected by the virus to promote protective immunity, but the lack of CD8⁺ T seems to have no effect in preventing arthrophlogosis of the infected mice (77). On the contrary, the virus will not be able to induce joint diseases after the exhaustion of CD4⁺ T cells (77, 78). Activated CD4⁺ T cells have been shown to be implicated in the pathogenesis of arthrosis swell (77–79).

Unconventional $\gamma\delta T$ cells are also likely involved in promoting protective immunity in the host against chikungunya invasion. The numbers of $\gamma\delta T$ cells in the feet and lymph nodes are significantly increased after the mice are infected by chikungunya. Mice defective in $\gamma\delta T$ cells are more susceptible to chikungunya infection, exhibiting more severe foot swell and inflammation in the ankles, as well as increased oxidative damages, suggesting that $\gamma\delta T$ cells play critical roles in the protective immunity during the infection of chikungunya and subsequent inflammation and tissue damage (80).

Rift Valley Fever

Rift Valley Fever is a type of zoonosis caused by Rift Valley Fever virus, transmitted mainly by aedes and culex (26). Although most of infected patients only have minor fever, headache, and muscle pains, some patients may develop serious symptoms, including retinopathy, meningoencephalitis symptoms, and hemorrhagic fever (27). A possible role for $\gamma \delta T$ cells in Rift Valley Fever has been reported for infected sheep. Similar to other ruminants, the sheep's $\gamma \delta T$ cells account for a major population of its peripheral blood mononuclear cells. When recombinant Rift Valley Fever vaccine has been injected into the sheep, the percentage of CD11b⁺ $\gamma \delta T$ in its peripheral blood mononuclear cells can be significantly increased, suggesting that these cells may be critical for the host responses in respond to the virus infection (28).

Yellow fever virus

Yellow fever virus belongs to the Flaviviridae, transmitted primarily by aedes and haemophilus mosquito. The symptoms for yellow fever commonly include fever, headache, jaundice, muscle pains, and emesia. Some patients may develop more serious symptoms and die quickly (29). So far, the YF-17D vaccine for yellow fever is probably one of the most effective vaccines. When it is inoculated into human hosts, $\gamma\delta$ 2T cells can respond quickly and produce IFN- γ within a week (28).

Dengue fever

Dengue virus is a mosquito-borne pathogen that is transmitted between hosts by mosquito bite (30). In clinic, most patients with slight infection will not have complications, and only a small population of patients will progress into severe disease states, exhibiting thrombocytopenia, end-organ damage, and other symptoms (31). critically ill patients commonly develop secondary infection, which is closely related with innate immunity (32, 33). In the host immunity, T cells are critical for eliminating pathogen invasion. In *in vitro* experiments, CD8⁺ $\alpha\beta$ T cells can respond to dengue virus, and many evidence have shown that these cells play important roles in the host responses (34, 35).

We know relatively less about the roles for $\gamma\delta$ T cells in the dengue virus infection. Eleonora Cimini and colleagues analyzed peripheral blood mononuclear cells from 15 dengue fever patients, the results show a significant decrease of y82-T-cell frequency and an increase of failure markers. In addition, the ability of $\gamma \delta 2$ -T-cells to produce IFN- γ in response to the phosphor-antigen was limited (36). Interestingly, primary human $\gamma\delta T$ has been shown to be able to kill dengue virus in vitro, suggesting a potential role for these cells in the anti-dengue virus process. Further investigations by Chen-Yu Tsai and colleagues have shown that primary $\gamma \delta T$ cells serve as the early source of IFN-7 during dengue virus infection and promote the host immune responses by eliminating the virus-infected cells. Monocytes can act as helper cells to participate in the virus infection and enhance the immune reponses in an IL-18dependent manner (37).

Zika virus

Similar to dengue virus, Zica virus is primarily transmitted by infected aedes mosquitoes in tropical and subtropical regions. The infection of Zica virus can cause Guillain-Barre syndrome, neuropathy and myelitis. The infection during pregnancy may lead to the development of microcephaly and other congenital abnormalities in fetuses and newborns (38), and there has been a lack of clear treatment strategy. Previous reports have shown significantly increased Th1, Th2, Th9, and Th17 during acute Zica infection (39), suggesting that conventional T cells may dominate the host responses to Zica invasion. However, it should be noted that Eleonora Cimini and colleagues have also specifically detected $\gamma\delta 2$ TCR in Zika virus-infected patients and a significantly increased expression level of CD3⁺CD4⁻CD8⁻ T cell subsets (40), implying a possible role for unconventional $\gamma\delta$ T cells.

West Nile virus

West Nile virus is a type of flavivirus, primarily transmitted by culex pipiens. Most West Nile virus-infected patients exhibit no significant symptoms (asymptomatic). However, the incidence of severe cases increases significantly in immunocompromised populations (41), and there is no targeted vaccine for such cases. $\gamma\delta T$ cells are thought to play an essential role in the early control of infection. They respond rapidly by producing large amounts of IFN- γ (42). In addition to serving as the main source of IFN-y, yoT cells may also promote DC maturation and CD4⁺ T cell infiltration, as suggested by the observations that the expression of the dendric CD40, CD80, CD86 and MHC II molecules, as well as the expression of IL-12, are lower in $\gamma\delta T$ -deficient mice compared to those in wild-type mice. Furthermore, West Nile virus-induced activated $\gamma\delta T$ cells can promote the maturation of DC and the initiation and excitation of CD4⁺ cells (43) to combat against virus invasion.

Besides of above-mentioned roles, West Nile virus-activated $\gamma \delta T$ cells are also critical for limiting the invasion of the virus into the brain central vervous system, which is essential for protecting most infected-hosts from developing fatal encephalitis. Thomas Welte and colleagues have shown that, compared with young mice, older/aged mice are more susceptible to virus infection and have slower Vg1⁺ responses


but more Vg4⁺ cells, which in turn produce TNF- α , a factor implicated in the destruction of the blood-brain barrier. On the other hand, low Vg4⁺ cells will allow the virus load in the brain, whereby reducing the mortality rate of virus-caused severe encephalitis (44). In the acquired immunity against West Nile virus infection, $\gamma\delta T$ cells also actively participate in the host defense process, and decreased memory responses of CD81⁺ T cells likely easily lead to secondary infection of the virus in $\gamma\delta T$ deficient mice (45).

Mosquito-borne parasite

Malaria

Malaria is estimated to affect more than 200 million people each year (46). It is an arbo-borne disease transmitted by the bite of mosquito-borne plasmodium parasite. Despite more and more significant progresses in the control and reduction of malaria cases in the past decade, it still remains a major threat to global health (47). After invading into the host, malaria parasites parasitize their spores in the liver of the host, then start to grow and eventually form merozoites to invade red blood cells, leading to significant clinical symptoms and death (48, 49).

The invasion of plasmodium parasites can cause complicated immune responses, including humoral and cellular immunity responses. We have very limited knowledge about the nature of these responses, especially the cellular immunity responses. Previously, it has been reported that $\gamma\delta T$ cells can be activated by phosphor-antigen of the parasites (50),



also bind to the infected cells, release granzymes and granulysin, and kill the invaded plasmodium parasites and infected red blood cells

10.3389/fimmu.2022.965503

leading to a quick increase of $\gamma\delta T$ cells, especially the Vg9Vd2 subpopulation (51, 52) (Figure 2). Such activation and/or expansion of $\gamma\delta T$ cells appear to be persistent after the invasion of the plasmodium parasites and can occur during secondary infections (53–55). It is already known that the main cause of the high morbidity and mortality of malaria patients is the successful survival and exponential proliferation of plasmodium parasites within the host blood. In the supernatants from the co-culture of plasmodium parasites, $\gamma\delta T$ cells can be specifically expanded and promoted to acquire the parasite-lysing potential through the up-regulated expression of IFN- γ and other cytotoxic effector proteins.

Subsequently, $\gamma \delta T$ cells can directly kill plasmodium parasite-infected red blood cells to prevent or attenuate further infections (56) (Figure 2). These killer cells can bind to the infected red blood cells, release granzymes and granulysin to kill the invaded plasmodium parasites (46). Therefore, a decrease of the numbers of $\gamma \delta T$ cells may reversely facilitate the tolerance of plasmodium parasites. Accordingly, repeated plasmodium parasites infection may contribute to the development of clinical immunity in children living in plasmodium parasitesinfested regions, which is characterized by decreased numbers of patients with clear symptoms, accompanied by increased numbers of asymptomatic patients (57, 58).

During the repeated plasmodium parasites infections, the numbers of $\gamma \delta 2^+ \gamma \delta T$ cells will be decreased in the peripheral blood, along with down-regulated production of cytokines and up-regulated immune-related factors. As such, repeated plasmodium parasites infections in the childhood will drive a progressive loss of the $\gamma \delta 2^+ \gamma \delta T$ cells, leading to increased immune tolerance of the patients to plasmodium parasites (59).

Notably, besides above-mentioned anti-pathogen roles, $\gamma \delta T$ cells may also have a paradoxical role in driving or participating in the pathogenesis of cerebral malaria, as the incidences of cerebral malaria complications is lower in infants with lower $\gamma \delta T$ reactivity. Julie Ribot and colleagues have shown that the $\gamma \delta T$ -deficient mice are more resistant to the development of cerebral malaria when infected with the plasmodium berghei ANKA sporozoa. Conversely, the presence of $\gamma \delta T$ cells can enhance the production of the plasmodium immune factors at the stage of liver infection and subsequently promote the inflammation reactions at the blood infection stage (60). Together, these findings demonstrate that $\gamma \delta T$ cells can promote the pathogenesis of IFN- γ -dependent plasmodium infection.

Immune responses of the host $\gamma\delta T$ cells to tick-borne pathogens

Borrelia burgdorferi

Compared to mosquito-borne pathogens, there have been less reports regarding the roles of $\gamma\delta T$ cells in the infection of tick-borne pathogens. The Lyme disease is the most frequently

seen natural epidemic disease in the United States of America (61) and is transmitted through bites from different hosts by borrelia burgdorferi-carrying ticks (62). Initial symptoms after the pathogen invasion in most Lyme disease patients are characterized by chronic erythema migrans. Several weeks after the disease onset, some patients may develop neurological and cardiac problems. After several months, most patients will have recurrent symptoms such as joint pain or arthritis (63). Under the stimulation by borbora burgdorferi, an accumulation can be detected within the inflated joints of the patients (64), suggesting a possible role for these cells in the host immune responses to the pathogen. Similarly, proliferated y\deltaT cells have also been detected in leukocytes from micewith Lyme disease and in human peripheral blood after tick bites (65). However, the responses of $\gamma\delta T$ cells may be indirectly through the actions of Toll-like receptors of DCs or monocytes, rather than through a direct mechanism by themselves (64). In addition, $\gamma\delta T$ cells may also act to activate the host acquired immunity during the infection of the pathogen (66).

Tularaemia

The pathogen for tularaemia is Francisella tularensis, a type of gram-negative bacterium, which can be transmitted by tick bites from different hosts and cause acute febrile disease (67). Increased numbers of $\gamma\delta T$ cells can be detected in the blood from tularaemia patients (67), possibly attributable to non-specific phosphor-molecules (68). Further investigations by M. KROCA and colleagues have revealed that the frequency of $\gamma\delta T$ cells can be increased and maintained for up tyo a year in the peripheral blood from tularaemia patients (69).

Immune responses of the host $\gamma\delta T$ cells to other vector-borne diseases

Leishmaniasis

Leishmaniasis is disease caused by the infection of leishmania and primarily transmitted by the bites from different hosts by leishmania-infected female diptera insect phlebotomus fly. Leishmaniasis can be categorized into three major subtypes, including visceral leishmaniasis, cutaneous leishmaniasis, and mucocutaneous leishmaniasis. Visceral leishmaniasis is also called kala-azar (black sickness) and is the most severe subtype of leishmaniasis. Visceral leishmaniasis leads to symptoms including irregular fever, weight loss, hepatosplenomegaly, and anamenia, and may eventually cause patient death. Cutaneous leishmaniasis is the most popular subtype and mainly causes skin ulcer. Mucocutaneous leishmaniasis mainly causes mucous membrane injury within the oral and nasal cavity. Leishmania belongs to parasites, and cellular immunity plays a central role in the host responses to its infection. An accumulation of $\gamma\delta T$ cells has been detected in the skin and blood from human hosts infected with leishmania (70,

10.3389/fimmu.2022.965503

71), suggesting a potential role for $\gamma\delta T$ cells in eliminating the infected parasites. Consistently, it has been reported that natural killer cells and $\gamma\delta T$ cells act through secreting INF- γ and TNF- α , respectively, to exert their functions in the host innate immunity against the leishmania invasion (72). Compared with healthy individuals, double negative T cells from about 75% of the cutaneous leishmaniasis patients express a βT cell receptors, and the rest of the double negative T cells express $\gamma\delta T$ cell receptors (73). In addition, dogs severely infected with leishmania may develop $\gamma\delta T$ cell lyphoma (71), suggesting that long-term stimulation by leishmania may lead to malignant transformation and lyphoma pathogenesis, but the underlying mechanism has been unclear.

South American trypanosomiasis

South American trypanosomiasis is also known as Chagas' disease and mainly caused by direct contact with the excrement or urinate of Trypanosoma cruzi-infected trypanosoma triatoroae (stink bug). Currently there is no vaccine available for this disease. During the acute stage, the infected patients mainly exhibit symptoms including cyanosis swelling on one side of the skin or eyelid, headache, difficulty in breath, and muscle pains. At the chronic stage, the parasites parasitize in the intestine tracts and the heart. Years later after the infection, some patients may develop heart and digestive tract diseases. By utilizing $\gamma\delta T$ cell-deficient mice as a model, a recent report has shown that the $\gamma\delta T$ cells may not play a critical role in the elimination of the parasites at the acute stage of the disease but may contribute to tissue damage and pathogenesis. In cutaneous leishmaniasis patients, $\alpha\beta T$ cells and $\gamma\delta T$ cells secret inflammatory factors and IL-10, respectively to protect the hosts against the parasites invasion (74). Moreover, the frequency of IL-10 expression by $\gamma\delta T$ cells have been linked to an improvement of cardiac functions of cutaneous leishmaniasis patients, suggesting a potentially important role for $\gamma\delta T$ cells in the host responses (74).

Conclusions

It is estimated that vector-borne diseases lead to more than half million of global deaths each year, and some types of vectorborne diseases, such as chikungunya, leishmaniasis, and lymphatic filariasis may cause life-long diseases. Vaccines or other clinically effective drugs for many vector-borne diseases are still lacking, further worsening the life quality of the infected patients. As such, understanding better the host-pathogen interactions is critical for future developing novel and curative therapeutics.

Compared to unconventional $\gamma\delta T$ cells, the role for conventional $\alpha\beta T$ cells in the host responses to vector-borne pathogens has been more extensively and comprehensively

studied, for instance Chikungunya virus (81–83), Rift Valley Fever virus (28), Yellow fever virus (84, 85), Zika virus (86, 87), West Nile virus (88), Malaria (89, 90), Borrelia burgdorferi (91), and Leishmaniasis (73, 92). However, as above-reviewed, our understanding of the role for $\gamma\delta T$ cells in these processes has been preliminary and incomplete.

It should be noted that most types of pathogens for vectorborne diseases are carried and disseminated by mosquitos and ticks, which transmitted the pathogens through the bites of host skin (93, 94). Given that $\gamma\delta T$ cells primarily reside in skin and mucosal tissues (95), these cells apparently are in the frontline to respond to pathogen invasion at the earliest stage. Therefore, it is important and urgent to gain a better understanding of the role for $\gamma\delta T$ cells during these precesses.

Previous studies have shown that $\alpha\beta T$ and $\gamma\delta T$ cells cooperate with each other and act synergistically towards eliminating pathogen invasion. As a bridge between innate and adaptive immunity, $\gamma\delta T$ cells have been known to play active roles during the first and secondary infections by pathogens and may serve as targets for clinical development. However, we still have limited knowledge about details of how they appropriately respond to vector-borne pathogen infection to facilitate the host immune responses.

During the early events of pathogen infection, activated $\gamma\delta T$ cells can secret multiple cytokines and inflammatory factors to induce the acquired immunity (96–98). Further studies in rodent models of infection of listeria, cytomegalovirus, and plasmodium parasites have revealed that $\gamma\delta T$ cells can strongly respond and quickly expand during secondary infections, suggesting that they have acquired certain levels of immune memory. These findings also suggest that the mode by which $\gamma\delta T$ cells respond to pathogen infections may be more complicated than previously appreciated.

Herein, we have reviewed recent findings related to the potential roles of $\gamma\delta T$ cells in response to several types of vector-borne pathogens, especially the mosquito- and tick-borne pathogens. We expect that these findings, together with those from more studies to analyze the interactions between $\gamma\delta T$ cells and vector-borne pathogens in the future, will provide useful information for developing clinically relevant targeted therapeutics.

Author contributions

CC and YY wrote the manuscript; AC and YY contributed to figures in this manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Acknowledgments

This work was partly supported by a junior faculty start-up fund from Anhui Medical University (to CC). We apologize for

not being able to cite all important literatures in the field due to space limit.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Endo A, Amarasekare P. Predicting the spread of vector-borne diseases in a warming world. *Front Ecol Evol* (2022) 10. doi: 10.3389/fevo.2022.758277

2. Lima AR, Dias LD, Garbuio M, Inada NM, Bagnato VS. A look at photodynamic inactivation as a tool for pests and vector-borne diseases control. *Laser Phys Lett* (2022) 19:025601. doi: 10.1088/1612-202X/ac4591

3. Chala B, Hamde F. Emerging and re-emerging vector-borne infectious diseases and the challenges for control: A review. *Front Public Health* (2021) 9:715759. doi: 10.3389/fpubh.2021.715759

4. Savic S, Vidic B, Grgic Z, Potkonjak A, Spasojevic L. Emerging vector-borne diseases - incidence through vectors. *Front Public Health* (2014) 2:267. doi: 10.3389/fpubh.2014.00267

5. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. *Nat Med* (2004) 10:S70–76. doi: 10.1038/nm1150

6. Chien YH, Meyer C, Bonneville M. Gammadelta T cells: first line of defense and beyond. *Annu Rev Immunol* (2014) 32:121–55. doi: 10.1146/annurev-immunol-032713-120216

7. Caccamo N, Dieli F, Wesch D, Jomaa H, Eberl M. Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. *J Leukoc Biol* (2006) 79:663–6. doi: 10.1189/jlb.1105640

8. Morath A, Schamel WW. Alpha beta and gamma delta T cell receptors: Similar but different. *J Leuk Biol* (2020) 107:1045–55. doi: 10.1002/JLB.2MR1219-233R

9. Herrmann T, Karunakaran MM, Fichtner AS. A glance over the fence: Using phylogeny and species comparison for a better understanding of antigen recognition by human gamma delta T-cells. *Immunol Rev* (2020) 298:218–36. doi: 10.1111/imr.12919

10. Castro CD, Boughter CT, Broughton AE, Ramesh A, Adams EJ. Diversity in recognition and function of human gamma delta T cells. *Immunol Rev* (2020) 298:134–52. doi: 10.1111/imr.12930

11. Papotto PH, Yilmaz B, Silva-Santos B. Crosstalk between gamma delta T cells and the microbiota. *Nat Microbiol* (2021) 6:1110–7. doi: 10.1038/s41564-021-00948-2

12. Wu XX, Gu B, Yang H. The role of gamma delta T cells in the interaction between commensal and pathogenic bacteria in the intestinal mucosa. *Int Rev Immunol* (2022). doi: 10.1080/08830185.2022.2076846

13. Zhao Y, Lin L, Xiao Z, Li M, Wu X, Li W, et al. Protective role of gammadelta T cells in different pathogen infections and its potential clinical application. *J Immunol Res* (2018) 2018:5081634. doi: 10.1155/2018/5081634

14. Qu GY, Wang SL, Zhou ZL, Jiang DW, Liao AH, Luo J, et al. Comparing mouse and human tissue-resident gamma delta T cells. *Front Immunol* (2022) 13. doi: 10.3389/fimmu.2022.891687

15. Chen ZW. Protective immune responses of major Vgamma2Vdelta2 T-cell subset in m. *Tuberculosis Infect Curr Opin Immunol* (2016) 42:105–12. doi: 10.1016/j.coi.2016.06.005

16. Zhong H, Hu X, Janowski AB, Storch GA, Su L, Cao L, et al. Whole transcriptome profiling reveals major cell types in the cellular immune response against acute and chronic active Epstein-Barr virus infection. *Sci Rep* (2017) 7:17775. doi: 10.1038/s41598-017-18195-z

17. Cimini E, Sacchi A, Minicis S, De Bordoni V, Casetti R, Grassi G, et al. Vdelta2 T-cells kill ZIKV-infected cells by NKG2D-mediated cytotoxicity. *Microorganisms* (2019) 7:350. doi: 10.3390/microorganisms7090350

18. Agrati C, Castilletti C, Cimini E, Romanelli A, Lapa D, Quartu S, et al. Antiviral activity of human Vdelta2 T-cells against WNV includes both cytolytic and non-cytolytic mechanisms. *New Microbiol* (2016) 39:139–42.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

19. Mangan BA, Dunne MR, O'Reilly VP, Dunne PJ, Exley MA, O'Shea D, et al. Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vdelta3 T cells. *J Immunol* (2013) 191:30–4. doi: 10.4049/jimmunol.1300121

20. Ferrick DA, Schrenzel MD, Mulvania T, Hsieh B, Ferlin WG, Lepper H. Differential production of interferon- γ and interleukin-4 in response to Th1- and Th2-stimulating pathogens by $\gamma\delta$ T cells *in vivo. Nature* (1995) 373:255–7. doi: 10.1038/373255a0

21. Lawand M, Dechanet-Merville J, Dieu-Nosjean MC. Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications. *Front Immunol* (2017) 8. doi: 10.3389/fimmu.2017.00761

22. Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. *Expert Opin Pharmacother* (2015) 16:159–77. doi: 10.1517/14656566.2015.993381

23. Burt FJ, Chen WQ, Miner JJ, Lenschow DJ, Merits A, Schnettler E, et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. *Lancet Infect Dis* (2017) 17:E107–17. doi: 10.1016/S1473-3099(16) 30385-1

24. Cunha RVD, Trinta KS. Chikungunya virus: clinical aspects and treatment - a review. *Mem Inst Oswaldo Cruz* (2017) 112:523-31. doi: 10.1590/0074-02760170044

25. van Aalst M, Nelen CM, Goorhuis A, Stijnis C, Grobusch MP. Long-term sequelae of chikungunya virus disease: A systematic review. *Travel Med Infect Di* (2017) 15:8–22. doi: 10.1016/j.tmaid.2017.01.004

26. Linthicum KJ, Britch SC, Anyamba A. Rift valley fever: An emerging mosquito-borne disease. *Annu Rev Entomol* (2016) 61:395. doi: 10.1146/ annurev-ento-010715-023819

27. Hise AG, Traylor Z, Hall NB, Sutherland LJ, Dahir S, Ermler ME, et al. Association of symptoms and severity of rift valley fever with genetic polymorphisms in human innate immune pathways. *PloS Negl Trop D* (2015) 9: e0003584. doi: 10.1371/journal.pntd.0003584

 Lebedev M, Faburay B, Richt JA, Young A. Myeloid-like gammadelta T cell subset in the immune response to an experimental rift valley fever vaccine in sheep. *Vet Immunol Immunopathol* (2021) 233:110184. doi: 10.1016/j.vetimm.2021. 110184

29. Litvoc MN, Novaes CTG, Lopes MIBF. Yellow fever. Rev Assoc Med Bras (2018) 64:106–13. doi: 10.1590/1806-9282.64.02.106

30. Whitehorn J, Farrar J. Dengue. Brit Med Bull (2010) 95:161-73. doi: 10.1093/bmb/ldq019

31. Halstead SB. Dengue. Lancet (2007) 370:1644-52. doi: 10.1016/S0140-6736 (07)61687-0

32. Jayachandran B, Chanda K, Balamurali MM. Overview of pathogenesis, diagnostics, and therapeutics of infectious diseases: Dengue and zika. *ACS Omega* (2021) 6:22487–96. doi: 10.1021/acsomega.1c03536

33. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. *Nat Rev Dis Primers* (2016) 2:16055. doi: 10.1038/nrdp.2016.55

34. Bukowski JF, Kurane I, Lai CJ, Bray M, Falgout B, Ennis FA. Dengue virusspecific cross-reactive Cd8+ human cyto-toxic T-lymphocytes. *J Virol* (1989) 63:5086–91. doi: 10.1128/jvi.63.12.5086-5091.1989

35. Weiskopf D, Angelo MA, Azeredo EL, de Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8(+) T cells. *P Natl Acad Sci USA* (2013) 110:E2046–53. doi: 10.1073/pnas.1305227110

36. Cimini E, Grassi G, Beccacece A, Casetti R, Castilletti C, Capobianchi MR, et al. In acute dengue infection, high TIM-3 expression may contribute to the

impairment of IFNgamma production by circulating Vdelta2 T cells. Viruses (2022) 14:130. doi: 10.3390/v14010130

37. Tsai CY, Liong KH, Gunalan MG, Li N, Lim DS, Fisher DA, et al. Type I IFNs and IL-18 regulate the antiviral response of primary human gammadelta T cells against dendritic cells infected with dengue virus. *J Immunol* (2015) 194:3890–900. doi: 10.4049/jimmunol.1303343

38. Wang ZY, Wang PG, An J. Zika virus and zika fever. Virol Sin (2016) 31:103–9. doi: 10.1007/s12250-016-3780-y

39. Tappe D, Perez-Giron JV, Zammarchi L, Rissland J, Ferreira DF, Jaenisch T, et al. Cytokine kinetics of zika virus-infected patients from acute to reconvalescent phase. *Med Microbiol Immun* (2016) 205:269–73. doi: 10.1007/s00430-015-0445-7

40. Cimini E, Castilletti C, Sacchi A, Casetti R, Bordoni V, Romanelli A, et al. Human zika infection induces a reduction of IFN-gamma producing CD4 T-cells and a parallel expansion of effector Vdelta2 T-cells. *Sci Rep* (2017) 7:6313. doi: 10.1038/s41598-017-06536-x

41. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile Virus. Lancet Infect Dis (2002) 2:519–29. doi: 10.1016/S1473-3099(02)00368-7

42. Wang T, Scully E, Yin ZN, Kim J, Yan J, Mamula M, et al. IFN-gammaproducing gammadelta T cells help control murine West Nile virus infection. *FASEB J* (2004) 18:A806–7. doi: 10.4049/jimmunol

43. Fang H, Welte T, Zheng X, Chang GJ, Holbrook MR, Soong L, et al. Gammadelta T cells promote the maturation of dendritic cells during West Nile virus infection. *FEMS Immunol Med Microbiol* (2010) 59:71–80. doi: 10.1111/j.1574-695X.2010.00663.x

44. Welte T, Lamb J, Anderson JF, Born WK, O'Brien RL, Wang T. Role of two distinct gammadelta T cell subsets during West Nile virus infection. *FEMS Immunol Med Microbiol* (2008) 53:275–83. doi: 10.1111/j.1574-695X.2008.00430.x

45. Wang T, Gao Y, Scully E, Davis CT, Anderson JF, Welte T, et al. Gamma delta T cells facilitate adaptive immunity against West Nile virus infection in mice. *J Immunol* (2006) 177:1825–32. doi: 10.4049/jimmunol.177.3.1825

46. Hernandez-Castaneda MA, Happ K, Cattalani F, Wallimann A, Blanchard M, Fellay I, et al. Gammadelta T cells kill plasmodium falciparum in a granzymeand granulysin-dependent mechanism during the late blood stage. *J Immunol* (2020) 204:1798–809. doi: 10.4049/jimmunol.1900725

47. Dantzler KW, Jagannathan P. Gammadelta T cells in antimalarial immunity: New insights into their diverse functions in protection and tolerance. *Front Immunol* (2018) 9:2445. doi: 10.3389/fimmu.2018.02445

48. Sturm A, Amino R, Sand C, van de Regen T, Retzlaff S, Rennenberg A, et al. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. *Science* (2006) 313:1287–90. doi: 10.1126/science.1129720

49. Miller LH, Ackerman HC, Su XZ, Wellems TE. Malaria biology and disease pathogenesis: insights for new treatments. *Nat Med* (2013) 19:156–67. doi: 10.1038/ nm.3073

50. Eberl M. What you, too, should know about BTN2A1 antigen recognition by human gamma delta T cells: one step closer to knowing. *Immunol Cell Biol* (2020) 98:351–4. doi: 10.1111/imcb.12334

51. Deroost K, Langhorne J. Gamma/Delta T cells and their role in protection against malaria. *Front Immunol* (2018) 9. doi: 10.3389/fimmu.2018.02973

52. Costa G, Loizon S, Guenot M, Mocan I, Halary F, de Saint-Basile G, et al. Control of plasmodium falciparum erythrocytic cycle: gammadelta T cells target the red blood cell-invasive merozoites. *Blood* (2011) 118:6952–62. doi: 10.1182/blood-2011-08-376111

53. Galley HF, Lowes DA, Thompson K, Wilson ND, Wallace CA, Webster NR. Characterisation of gamma delta (gammadelta) T cell populations in patients with sepsis. *Cell Biol Int* (2015) 39:210–6. doi: 10.1002/cbin.10361

54. Matsushima A, Ogura H, Fujita K, Koh T, Tanaka H, Sumi Y, et al. Early activation of gammadelta T lymphocytes in patients with severe systemic inflammatory response syndrome. *Shock* (2004) 22:11–5. doi: 10.1097/01.shk.0000129203.84330.b3

55. Mamedov MR, Scholzen A, Nair RV, Cumnock K, Kenkel JA, Oliveira JHM, et al. A macrophage colony-Stimulating-Factor-Producing gammadelta T cell subset prevents malarial parasitemic recurrence. *Immunity* (2018) 48:350–363 e357. doi: 10.1016/j.immuni.2018.01.009

56. Junqueira C, Polidoro RB, Castro G, Absalon S, Liang Z, Sen Santara S, et al. Gamma delta T cells suppress plasmodium falciparum blood-stage infection by direct killing and phagocytosis. *Nat Immunol* (2021) 22:347–57. doi: 10.1038/ s41590-020-00847-4

57. Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nat Rev Immunol (2005) 5:722–35. doi: 10.1038/nri1686

58. Portugal S, Moebius J, Skinner J, Doumbo S, Doumtabe D, Kone Y, et al. Exposure-dependent control of malaria-induced inflammation in children. *PloS Pathog* (2014) 10:e1004079. doi: 10.1371/journal.ppat.1004079

59. Jagannathan P, Kim CC, Greenhouse B, Nankya F, Bowen K, Eccles-James I, et al. Loss and dysfunction of Vdelta2(+) gammadelta T cells are associated with

clinical tolerance to malaria. Sci Transl Med (2014) 6:251ra117. doi: 10.1126/ scitranslmed.3009793

60. Ribot JC, Neres R, Zuzarte-Luis V, Gomes AQ, Mancio-Silva L, Mensurado S, et al. Gammadelta-T cells promote IFN-gamma-dependent plasmodium pathogenesis upon liver-stage infection. *Proc Natl Acad Sci USA* (2019) 116:9979–88.

61. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP, et al. Lyme-Disease - a tick-borne spirochetosis. *Science* (1982) 216:1317–9. doi: 10.1126/science.7043737

62. Steere AC. Lyme-Disease. New Engl J Med (1989) 321:586–96. doi: 10.1056/ NEJM198908313210906

63. Rahn DW. Lyme-Disease - clinical manifestations, diagnosis, and treatment. Semin Arthritis Rheu (1991) 20:201-18. doi: 10.1016/0049-0172(91)90017-T

64. Collins C, Shi C, Russell JQ, Fortner KA, Budd RC. Activation of gamma delta T cells by borrelia burgdorferi is indirect *via* a TLR- and caspase-dependent pathway. *J Immunol* (2008) 181:2392–8. doi: 10.4049/jimmunol.181.4.2392

65. Seth M B. Martin, * Richard flowers, MD,† Arturo p. saavedra, MD, PhD, MBA,†, m. and alejandro a. gru, a reactive peripheral gamma-delta T-cell lymphoid. *Am J Dermatopathol* (2019) 41:e73-5. doi: 10.1097/DAD. 00000000001352

66. Shi CX, Sahay B, Russell JQ, Fortner KA, Hardin N, Sellati TJ, et al. Reduced immune response to borrelia burgdorferi in the absence of gamma delta T cells. *Infect Immun* (2011) 79:3940–6. doi: 10.1128/IAI.00148-11

67. Sumida T, Maeda T, Takahashi H, Yoshida S, Yonaha F, Sakamoto A, et al. Predominant expansion of V gamma 9/V delta 2 T cells in a tularemia patient. *Infect Immun* (1992) 60:2554–8. doi: 10.1128/iai.60.6.2554-2558.1992

68. Poquet Y, Kroca M, Halary F, Stenmark S, Peyrat MA, Bonneville M, et al. Expansion of Vγ9Vδ2 T cells is triggered byFrancisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. *Infect Immun* (1998) 66(5):2107–14. doi: 10.1128/IAI.66.5.2107-2114.1998

 Kroca M, Tärnvik A, Sjöstedt A. The proportion of circulating gd T cells increases after the first week of onset of. *Clin Exp Immunol* (2000) 120:280–4. doi: 10.1046/j.1365-2249.2000.01215.x

70. Modlin RL, Pirmez C, Hofman FM, Torigian V, Uyemura K, Rea TH, et al. Lymphocytes bearing antigen-specific gamma delta T-cell receptors accumulate in human infectious disease lesions. *Nature* (1989) 339:544–8. doi: 10.1038/339544a0

71. Welte T, Lamb J, Anderson JF, Born WK, O'Brien RL, Wang T, et al. Extranodal gammadelta-t-cell lymphoma in a dog with leishmaniasis. *Vet Clin Pathol* (2008) 37:298–301. doi: 10.1111/j.1939-165X.2008.00048.x

72. Lagler H, Willheim M, Traunmüller F, Wahl K, Winkler H, Ramharter M, et al. Cellular profile of cytokine production in a patient with visceral leishmaniasis: gammadelta+ T cells express both type 1 cytokines and interleukin-10. *Scand J Immunol* (2003) 57:291–5. doi: 10.1046/j.1365-3083.2003.01223.x

73. Antonelli LRV, Dutra WO, Oliveira RR, Torres KC, Guimarães LH, Bacellar O, et al. Disparate immunoregulatory potentials for double-negative (CD4(-) CD8 (-)) alpha beta and gamma delta T cells from human patients with cutaneous leishmaniasis. *Infect Immun* (2006) 74:6317–23. doi: 10.1128/IAI.00890-06

74. Villani FN, Rocha MO, Nunes Mdo C, Antonelli LR, Magalhães LM, dos Santos JS, et al. Trypanosoma cruzi-induced activation of functionally distinct alphabeta and gammadelta CD4- CD8- T cells in individuals with polar forms of chagas' disease. *Infect Immun* (2010) 78:4421–30. doi: 10.1128/IAI.00179-10

75. van den Hurk AF, Hall-Mendelin S, Pyke AT, Frentiu FD, McElroy K, Day A, et al. Impact of wolbachia on infection with chikungunya and yellow fever viruses in the mosquito vector aedes aegypti. *PloS Negl Trop D* (2012) 6:e1892. doi: 10.1371/journal.pntd.0001892

76. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. *N Engl J Med* (2015) 372:1231–9. doi: 10.1056/NEJMra1406035

77. Teo TH, Lum FM, Claser C, Lulla V, Lulla A, Merits A, et al. A pathogenic role for CD4(+) T cells during chikungunya virus infection in mice. *J Immunol* (2013) 190:259–69. doi: 10.4049/jimmunol.1202177

78. Poh CM, Chan YH, Ng LFP. Role of T cells in chikungunya virus infection and utilizing their potential in anti-viral immunity. *Front Immunol* (2020) 11:287. doi: 10.3389/fimmu.2020.00287

79. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. *J Immunol* (2010) 184:5914–27. doi: 10.4049/jimmunol.0900255

80. Long KM, Ferris MT, Whitmore AC, Montgomery SA, Thurlow LR, McGee CE, et al. Gammadelta T cells play a protective role in chikungunya virus-induced disease. *J Virol* (2016) 90:433–43. doi: 10.1128/JVI.02159-15

81. Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, Leroy EM. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. *J Infect Dis* (2011) 204:115–23. doi: 10.1093/infdis/jiq006

82. Poo YS, Rudd PA, Gardner J, Wilson JA, Larcher T, Colle MA, et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. *PloS Negl Trop D* (2014) 8:e3354. doi: 10.1371/journal.pntd.0003354

83. Ninla-aesong P, Mitarnun W, Noipha K. Proinflammatory cytokines and chemokines as biomarkers of persistent arthralgia and severe disease after chikungunya virus infection: A 5-year follow-up study in southern Thailand. *Viral Immunol* (2019) 32:442–52. doi: 10.1089/vim.2019.0064

84. Douam F, Soto Albrecht YE, Hrebikova G, Sadimin E, Davidson C, Kotenko SV, et al. Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection *in vivo*. *Mbio* (2017) 8(4):e00819–17. doi: 10.1128/mBio.00819-17

85. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8(+) T cell response. *J Immunol* (2009) 183:7919–30. doi: 10.4049/jimmunol.0803903

86. Wen JS, Tang WW, Sheets N, Ellison J, Sette A, Kim K, et al. Identification of zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8(+) T cells. *Nat Microbiol* (2017) 2:17036. doi: 10.1038/nmicrobiol.2017.36

87. Bullard BL, Corder BN, Gorman MJ, Diamond MS, Weaver EA. Efficacy of a T cell-biased adenovirus vector as a zika virus vaccine. *Sci Rep-Uk* (2018) 8:18017. doi: 10.1038/s41598-018-35755-z

88. Kim S, Pinto AK, Myers NB, Hawkins O, Doll K, Kaabinejadian S, et al. A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice. *Eur J Immunol* (2014) 44:1936–46. doi: 10.1002/eji.201444450

89. Hassan R, Franco SA, Stefanoff CG, Romano SO, Diamond HR, Franco LG, et al. Hepatosplenic gamma delta T-cell lymphoma following seven malaria infections. *Pathol Int* (2006) 56:668–73. doi: 10.1111/j.1440-1827.2006.02027.x

90. Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenenk R, de Mast Q, et al. Longevity and composition of cellular immune responses following experimental plasmodium falciparum malaria infection in humans. *PloS Pathog* (2011) 7:e1002389. doi: 10.1371/journal.ppat.1002389

91. Belperron AA, Dailey CM, Booth CJ, Bockenstedt LK. Marginal zone b-cell depletion impairs murine host defense against borrelia burgdorferi infection. *Infect Immun* (2007) 75:3354–60. doi: 10.1128/IAI.00422-07

92. Antonelli LR, Dutra WO, Oliveira RR, Torres KC, Guimarães LH, Bacellar O, et al. Disparate immunoregulatory potentials for CD4-CD8-alpha/beta and gamma/delta T cells from cutaneous leishmaniasis patients. *Am J Trop Med Hyg* (2007) 77:88–9. doi: 10.1128/IAI.00890-06

93. Cheng G, Liu Y, Wang PH, Xiao XP. Mosquito defense strategies against viral infection. *Trends Parasitol* (2016) 32:177–86. doi: 10.1016/j.pt.2015.09.009

94. Markowicz M, Schötta AM, Höss D, Kundi M, Schray C, Stockinger H, et al. Infections with tickborne pathogens after tick bite, Austria, 2015-2018. *Emerg Infect Dis* (2021) 27:1048–56. doi: 10.3201/eid2704.203366

95. Nielsen MM, Witherden DA, Havran WL. Gamma delta T cells in homeostasis and host defence of epithelial barrier tissues. *Nat Rev Immunol* (2017) 17:733–45. doi: 10.1038/nri.2017.101

96. Wang KQ, Hou YQ, Li QH, Zhao DP, Duan YC, Ran ZS, et al. Inhibitory effect of LY294002 on CD3mAb-activated T cells and mtb-ag-activated gamma delta T cells *via* TCR signal transduction pathway. *Int J Clin Exp Patho* (2017) 10:5538–44.

97. Wang KQ, Hou Y, Gu C, Zhao D, Duan Y, Ran Z, et al. Inhibitory effect of the mitogen activated protein kinase specific inhibitor PD98059 on mtb-agactivated gamma delta T cells. *Int J Clin Exp Patho* (2017) 10:9644–8.

98. Wang YR, Wang YS, Wang KQ. Research progress on the mechanism of gamma delta T cells in pathogenic microbial infection. *Int J Clin Exp Med* (2019) 12:9597–606.